Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Bosulif   
Auth. number : EU/1/13/818
INN : Bosutinib
Orphan status based on designation EU/3/10/762 added on 02/04/2013
ATC: Anatomical main group: L - Antineoplastic and immunomodulating agents
Therapeutic subgroup: L01 - Cytostatics
Pharmacological subgroup: L01X - Other cytostatics
Chemical subgroup: L01XE - Protein kinase inhibitors
Chemical substance: L01XE14 - Bosutinib
(See WHO ATC Index)
Indication: Bosulif is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Marketing Authorisation Holder: Pfizer Limited
Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/04/2013 Centralised - Authorisation EMEA/H/C/2373 (2013)1968 of 27/03/2013
24/02/2014 Centralised - Annual renewal EMEA/H/C/2373/R/2 (2014)1263 of 20/02/2014
22/05/2014 Centralised - Variation EMEA/H/C/2373/IB/6
Updated with Decision(2014)4368 of 23/06/2014
25/06/2014 Centralised - 2-Monthly update EMEA/H/C/2373/II/1 (2014)4368 of 23/06/2014
23/10/2014 Centralised - Variation EMEA/H/C/2373/II/8